PetBioCell is continuing its research into dendritic cell therapy and its potential applications in various diseases of dogs, cats and horses. In this context, PetBioCell is working together with the Research Centre for Medical Technology and Biotechnology (fzmb) on the development of improved end product control.
The aim is to reduce the number of cells required for end product control to a minimum using certain methods in order to provide patients with as many cells as possible for treatment. New methods are being developed to achieve this goal.
For the development and establishment of these methods, the research community of PetBioCell and fzmb receives funding from the Federal Ministry of Economics and Energy. The funds will be used to put the research results into practice for the benefit of patients.